Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $50.29.
Several analysts have commented on the stock. Berenberg Bank initiated coverage on shares of Harmony Biosciences in a research report on Thursday, September 7th. They set a “buy” rating and a $59.00 target price for the company. Piper Sandler reduced their target price on Harmony Biosciences from $72.00 to $42.00 and set an “overweight” rating on the stock in a report on Monday, October 16th. Raymond James lowered their price target on Harmony Biosciences from $58.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 16th. Needham & Company LLC reduced their price objective on shares of Harmony Biosciences from $66.00 to $53.00 and set a “buy” rating on the stock in a research note on Monday, October 16th. Finally, Mizuho restated a “buy” rating and set a $54.00 price objective on shares of Harmony Biosciences in a report on Wednesday, October 4th.
Institutional Trading of Harmony Biosciences
Harmony Biosciences Trading Down 1.9 %
Shares of Harmony Biosciences stock opened at $19.20 on Monday. The stock has a market capitalization of $1.15 billion, a P/E ratio of 5.87, a price-to-earnings-growth ratio of 0.59 and a beta of 0.47. The company has a quick ratio of 4.84, a current ratio of 4.90 and a debt-to-equity ratio of 0.37. The company has a 50-day simple moving average of $31.62 and a 200 day simple moving average of $33.58. Harmony Biosciences has a 12-month low of $18.61 and a 12-month high of $62.08.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.06). The company had revenue of $134.22 million during the quarter, compared to analyst estimates of $139.79 million. Harmony Biosciences had a net margin of 40.16% and a return on equity of 42.49%. Research analysts expect that Harmony Biosciences will post 2.39 earnings per share for the current fiscal year.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- Five stocks we like better than Harmony Biosciences
- How to Invest in Renewable Energy
- Is domestic travel back on track? Check out these companies
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 10/23 – 10/27
- What is the Nikkei 225 index?
- Can casino stocks win big if economy slows?
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.